Key result
Rotarix vaccine demonstrates substantial real-world reductions in rotavirus infections and hospitalizations over 15 years.
Why the study?
Rotavirus disease remains a prominent cause of disease burden in children under 5 years of age worldwide despite reductions in mortality following vaccination, prompting a review of 15 years of real-world experience.
Does the oral live-attenuated human rotavirus vaccine reduce RV disease burden and hospitalizations in children <5 years of age?
Does the oral live-attenuated human rotavirus vaccine reduce RV disease burden and hospitalizations in children <5 years of age?
The oral live-attenuated human rotavirus vaccine has demonstrated substantial real-world effectiveness in reducing RV infections and hospitalizations over 15 years of use.
Supports sustained rotavirus vaccination programs in children; leaves open need for ongoing strain surveillance and updated efficacy data.
Introduction Rotavirus (RV) disease remains a prominent cause of disease burden in children <5 years of age worldwide. However, implementation of RV vaccination has led to significant reductions in RV mortality, compared to the pre-vaccination era. This review presents 15 years of real-world experience with the oral live-attenuated human RV vaccine (HRV; Rotarix). HRV is currently introduced in ≥80 national immunization programs (NIPs), as 2 doses starting from 6 weeks of age.Areas covered The clinical development of HRV and post-marketing experience indicating the impact of HRV vaccination on RV disease was reviewed.Expert opinion In clinical trials, HRV displayed an acceptable safety profile and efficacy against RV-gastroenteritis, providing broad protection against heterotypic RV strains by reducing the consequences of severe RV disease in infants. Real-world evidence shows substantial, rapid reduction in the number of RV infections and associated hospitalizations following introduction of HRV in NIPs, regardless of economic setting. Indirect effects against RV disease are also observed, such as herd protection, decrease in nosocomial infections incidence, and a reduction of disease-related societal/healthcare costs. However, not all countries have implemented RV vaccination. Coverage remains suboptimal and should be improved to maximize the benefits of RV vaccination.
No takes yet. Share an insight, caveat, or question.
Pereira et al. (2020) conducted a review in Rotavirus (RV) disease. Oral live-attenuated human rotavirus vaccine (HRV; Rotarix) was evaluated. The oral live-attenuated human rotavirus vaccine (Rotarix) has demonstrated substantial, rapid reductions in rotavirus infections and hospitalizations over 15 years of real-world experience.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: